Aberdeen Group plc Takes $1.78 Million Position in Biodesix, Inc. $BDSX

Aberdeen Group plc purchased a new stake in shares of Biodesix, Inc. (NASDAQ:BDSX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 262,425 shares of the company’s stock, valued at approximately $1,784,000. Aberdeen Group plc owned approximately 3.30% of Biodesix at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of BDSX. XTX Topco Ltd increased its holdings in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Millennium Management LLC bought a new position in shares of Biodesix during the third quarter valued at $113,000. Finally, Oracle Investment Management Inc. bought a new position in shares of Biodesix during the third quarter valued at $113,000. 20.96% of the stock is currently owned by institutional investors.

Biodesix Price Performance

Biodesix stock opened at $13.32 on Friday. Biodesix, Inc. has a one year low of $3.44 and a one year high of $20.21. The stock has a market capitalization of $131.34 million, a PE ratio of -2.75 and a beta of 0.57. The business’s fifty day moving average is $14.15 and its 200 day moving average is $9.90.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.56. The business had revenue of $28.76 million for the quarter, compared to analysts’ expectations of $26.25 million. Biodesix had a negative return on equity of 1,760.83% and a negative net margin of 39.85%. As a group, sell-side analysts expect that Biodesix, Inc. will post -0.35 EPS for the current fiscal year.

Insider Activity

In other Biodesix news, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the transaction, the chief executive officer directly owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. This trade represents a 7.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack W. Schuler bought 82,465 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was purchased at an average cost of $10.96 per share, for a total transaction of $903,816.40. Following the completion of the transaction, the director directly owned 1,463,210 shares of the company’s stock, valued at approximately $16,036,781.60. The trade was a 5.97% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 182,465 shares of company stock worth $2,084,616 and sold 10,999 shares worth $116,095. Company insiders own 30.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. William Blair raised Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price objective on shares of Biodesix in a research report on Tuesday, February 17th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.